One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials
Milton Packer, Faiez Zannad, Stefan D. Anker
doi : 10.1161/CIRCULATIONAHA.121.056657
Circulation. 2021;144:1193–1195
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
Pieter C. Smits, Enrico Frigoli, Jan Tijssen, Peter Jüni, Pascal Vranckx, Yukio Ozaki, Marie-Claude Morice, Bernard Chevalier, Yoshinobu Onuma, Stephan Windecker, Pim A.L. Tonino, Marco Roffi, Maciej Lesiak, Felix Mahfoud, Jozef Bartunek, David Hildick-Smith, Antonio Colombo, Goran Stankovic, Andrés Iñiguez, Carl Schultz, Ran Kornowski, Paul J.L. Ong, Mirvat Alasnag, Alfredo E. Rodriguez, Aris Moschovitis, Peep Laanmets, Dik Heg, Marco Valgimigli, and on behalf of the MASTER DAPT Investigators
doi : 10.1161/CIRCULATIONAHA.121.056680
Circulation. 2021;144:1196–1211
The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear.
Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial
James A. Blumenthal, Alan L. Hinderliter, Patrick J. Smith, Stephanie Mabe, Lana L. Watkins, Linda Craighead, Krista Ingle, Crystal Tyson, Pao-Hwa Lin, William E. Kraus, Lawrence Liao, Andrew Sherwood
doi : 10.1161/CIRCULATIONAHA.121.055329
Circulation. 2021;144:1212–1226
Although lifestyle modifications generally are effective in lowering blood pressure (BP) among patients with unmedicated hypertension and in those treated with 1 or 2 antihypertensive agents, the value of exercise and diet for lowering BP in patients with resistant hypertension is unknown.
Myeloid-Derived Growth Factor Protects Against Pressure Overload–Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca2+-ATPase Expression in Cardiomyocytes
Mortimer Korf-Klingebiel, Marc R. Reboll, Felix Polten, Natalie Weber, Felix Jäckle, Xuekun Wu, Marinos Kallikourdis, Paolo Kunderfranco, Gianluigi Condorelli, Evangelos Giannitsis, Olga S. Kustikova, Axel Schambach, Andreas Pich, Julian D. Widder, Johann Bauersachs, Joop van den Heuvel, Theresia Kraft, Yong Wang, Kai C. Wollert
doi : 10.1161/CIRCULATIONAHA.120.053365
Circulation. 2021;144:1227–1240
Inflammation contributes to the pathogenesis of heart failure, but there is limited understanding of inflammation’s potential benefits. Inflammatory cells secrete MYDGF (myeloid-derived growth factor) to promote tissue repair after acute myocardial infarction. We hypothesized that MYDGF has a role in cardiac adaptation to persistent pressure overload.
Inflammation and Heart Failure: Friend or Foe?
Roger J. Hajjar, Jane A. Leopold
doi : 10.1161/CIRCULATIONAHA.121.056628
Circulation. 2021;144:1241–1243
Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 Signaling
Chenfeng Mao, Zihan Ma, Yiting Jia, Weihao Li, Nan Xie, Guizhen Zhao, Baihui Ma, Fang Yu, Jinpeng Sun, Yuan Zhou, Qinghua Cui, Yi Fu, Wei Kong
doi : 10.1161/CIRCULATIONAHA.120.053361
Circulation. 2021;144:1244–1261
How the extracellular matrix (ECM) microenvironment modulates the contractile phenotype of vascular smooth muscle cells (VSMCs) and confers vascular homeostasis remains elusive.
Atrioventricular Block With Narrow and Wide QRS: The Pause That Refreshes
Satoshi Higuchi, Nora Goldschlager, Edward P. Gerstenfeld
doi : 10.1161/CIRCULATIONAHA.121.055990
Circulation. 2021;144:1262–1264
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials
Stefan D. Anker, Piotr Ponikowski, Christoph Wanner, Egon Pfarr, Sibylle Hauske, Barbara Peil, Afshin Salsali, Ivana Ritter, Audrey Koitka-Weber, Martina Brueckmann, JoAnn Lindenfeld, William T. Abraham, and on behalf of the EMPERIAL Investigators and National Coordinators
doi : 10.1161/CIRCULATIONAHA.121.054669
Circulation. 2021;144:1265–1267
The American Heart Association’s Focus on Primordial Prevention
Donald M. Lloyd-Jones, Michelle A. Albert, Mitchell Elkind
doi : 10.1161/CIRCULATIONAHA.121.057125
Circulation. 2021;144:e233–e235
Letter by Wei and Fang Regarding Article, “Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies”
Jie Wei, Dalang Fang
doi : 10.1161/CIRCULATIONAHA.121.055647
Circulation. 2021;144:e236
Response by Filippini et al to Letter Regarding Article, “Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies”
Tommaso Filippini, Marcella Malavolti, Paul K. Whelton, Androniki Naska, Nicola Orsini, Marco Vinceti
doi : 10.1161/CIRCULATIONAHA.121.056311
Circulation. 2021;144:e237
Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association
Alanna A. Morris, Prateeti Khazanie, Mark H. Drazner, Nancy M. Albert, Khadijah Breathett, Lauren B. Cooper, Howard J. Eisen, Patrick O’Gara, Stuart D. Russell, and on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Hypertension
doi : 10.1161/CIR.0000000000001016
Circulation. 2021;144:e238–e250
Among the estimated 6.2 million Americans living with heart failure (HF), ?5%/y may progress to advanced, or stage D, disease. Advanced HF has a high morbidity and mortality, such that early recognition of this condition is important to optimize care. Delayed referral or lack of referral in patients who are likely to derive benefit from an advanced HF evaluation can have important adverse consequences for patients and their families. A 2-step process can be used by practitioners when considering referral of a patient with advanced HF for consideration of advanced therapies, focused on recognizing the clinical clues associated with stage D HF and assessing potential benefits of referral to an advanced HF center. Although patients are often referred to an advanced HF center to undergo evaluation for advanced therapies such as heart transplantation or implantation of a left ventricular assist device, there are other reasons to refer, including access to the infrastructure and multidisciplinary team of the advanced HF center that offers a broad range of expertise. The intent of this statement is to provide a framework for practitioners and health systems to help identify and refer patients with HF who are most likely to derive benefit from referral to an advanced HF center.
Call to Action: Maternal Health and Saving Mothers: A Policy Statement From the American Heart Association
Laxmi S. Mehta, Garima Sharma, Andreea A. Creanga, Afshan B. Hameed, Lisa M. Hollier, Janay C. Johnson, Lisa Leffert, Louise D. McCullough, Mahasin S. Mujahid, Karol Watson, Courtney J. White, and on behalf of the American Heart Association Advocacy Coordinating Committee
doi : 10.1161/CIR.0000000000001000
Circulation. 2021;144:e251–e269
The United States has the highest maternal mortality rates among developed countries, and cardiovascular disease is the leading cause. Therefore, the American Heart Association has a unique role in advocating for efforts to improve maternal health and to enhance access to and delivery of care before, during, and after pregnancy. Several initiatives have shaped the time course of major milestones in advancing maternal and reproductive health equity in the United States. There have been significant strides in improving the timeliness of data reporting in maternal mortality surveillance and epidemiological programs in maternal and child health, yet more policy reforms are necessary. To make a sustainable and systemic impact on maternal health, further efforts are necessary at the societal, institutional, stakeholder, and regulatory levels to address the racial and ethnic disparities in maternal health, to effectively reduce inequities in care, and to mitigate maternal morbidity and mortality. In alignment with American Heart Association’s mission “to be a relentless force for longer, healthier lives,” this policy statement outlines the inequities that influence disparities in maternal outcomes and current policy approaches to improving maternal health and suggests additional potentially impactful actions to improve maternal outcomes and ultimately save mothers’ lives.
